F Smaili1, A Boudjella2, A Dib3, S Braikia3, H Zidane3, R Reggad3, A Bendib4, A Abdelouahab4, F Bereksi-Reguig5, D Yekrou5, A Bentouati5, T Filali6, A Chirouf6, N Djehal6, H Mahfouf7, F Mechiat7, H Tadjerouni7, C Sedkaoui8, M Hikem8, A Amber8, K Bouzid9, A Ladjeroud9, S Ghomari10, H Aris10, S Saidi10, R Larhbali10, M A Saidi10, A Haddouche11, M Kedar12, A Bounedjar1, S Talha1, W Benbrahim13, A Ammari13, A Boushaba14, A Rabah14, N Ameziane14, F Benabdallah14, H Djedi15, N Kouadri15, A Bensalem16, S Djeghim16, M Oukkal17, F Hadjam17, B Larbaoui18, K Rekai18, N Azzouz18, A Badaoui19, M Abid20, M Abada21, A Moussei22, F Benmehidi23, N Benzidane4, K Boualga24, S Mesli24. 1. Université Blida 1, Laboratoire de Cancérologie, Faculté de médecine, BP 270, Route de Soumaa Blida 9000, Algeria. 2. Université Blida 1, Laboratoire de Cancérologie, Faculté de médecine, BP 270, Route de Soumaa Blida 9000, Algeria. Electronic address: aek.boudjella.onco@gmail.com. 3. Oncology department 19000 CAC SETIF, Algeria. 4. Surgery department 16000 CPMC « SENOLOGIE », Algeria. 5. Oncology department 22000 CHU SIDI BELABBES, Algeria. 6. Oncology department 25000 CHU CONSTANTINE, Algeria. 7. Oncology department 16000 EPH ROUIBA, Algeria. 8. Oncology department 15000 CHU TIZI OUZOU, Algeria. 9. Oncology department 16000 CPMC « ONCOLOGIE », Algeria. 10. Oncology department 13000 CHU TLEMCEN, Faculté de Médecine, Laboratoire Toxicomed, Université de Tlemcen, Algeria. 11. Medical And Regulatory Director Maghreb Astra Zeneca 16000, Algeria. 12. Oncology Medical Advisor Astra Zeneca 16000, Algeria. 13. Oncology department Center Anti Cancer Batna University Batna 2, 5000, Algeria. 14. Oncology department 31000 CHU ORAN, Algeria. 15. Oncology department 23000 CAC Annaba, Algeria. 16. Medical Oncology Department, 25000 EH DIDOUCHE Mourad, Faculte de médecin, Universite Constantine 3, Algeria. 17. Oncology department 16000 CHU BENI MESSOUS, Algeria. 18. Oncology department 31000 CAC ORAN, Algeria. 19. Oncology department 02000 EPH CHLEF, Algeria. 20. Surgery department 05000 CAC BATNA, Algeria. 21. Oncology department 44000 EPH AIN DEFLA, Algeria. 22. Oncology department 42000 EPH SIDI GHILES, Algeria. 23. Oncology department 26000 EPH MEDEA, Algeria. 24. Radiotherapy oncology department Centre Anti Cancer Zabana 09000, Blida.
Abstract
BACKGROUND: Breast cancer (BC) is a major health issue threatening women's life. No reliable epidemiological data on BC diagnosed by oncologists/senologists are available in Algeria. METHODS: The BreCaReAl study, a non-interventional prospective cohort study, included adult women with confirmed BC in Algeria. Disease incidence, patients and disease characteristics, treatment patterns, and mortality rate were recorded up to 12 months of follow-up. RESULTS: Overall, 1,437 patients were analysed: median age was 48 [41;57] years and 337 (23.5%) women had a family history of BC. BC incidence was 22.3 (95% CI: 21.5; 23.2) cases per 100,000 inhabitants over 8 months. Delayed diagnosis was reported in 400 (29.2%) patients. First line of treatments were mainly chemotherapy and surgery. Twenty-eight serious adverse events were reported including 10 (37.0%) events which led to death. Mortality rate reached 3.2% at 12 months CONCLUSION: A delayed diagnosis highlights the importance of implementing more effective screening strategies.
BACKGROUND:Breast cancer (BC) is a major health issue threatening women's life. No reliable epidemiological data on BC diagnosed by oncologists/senologists are available in Algeria. METHODS: The BreCaReAl study, a non-interventional prospective cohort study, included adult women with confirmed BC in Algeria. Disease incidence, patients and disease characteristics, treatment patterns, and mortality rate were recorded up to 12 months of follow-up. RESULTS: Overall, 1,437 patients were analysed: median age was 48 [41;57] years and 337 (23.5%) women had a family history of BC. BC incidence was 22.3 (95% CI: 21.5; 23.2) cases per 100,000 inhabitants over 8 months. Delayed diagnosis was reported in 400 (29.2%) patients. First line of treatments were mainly chemotherapy and surgery. Twenty-eight serious adverse events were reported including 10 (37.0%) events which led to death. Mortality rate reached 3.2% at 12 months CONCLUSION: A delayed diagnosis highlights the importance of implementing more effective screening strategies.